Literature DB >> 21975914

Multiple myeloma.

Kenneth C Anderson, Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Adam D Cohen, Steven Devine, Benjamin Djulbegovic, Edward A Faber, Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P Treon, Guido Tricot, Donna M Weber, Joachim Yahalom, Furhan Yunus.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21975914     DOI： 10.6004/jnccn.2011.0095

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  21 in total

1.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Authors:  Andrzej J Jakubowiak; Dominik Dytfeld; Kent A Griffith; Daniel Lebovic; David H Vesole; Sundar Jagannath; Ammar Al-Zoubi; Tara Anderson; Brian Nordgren; Kristen Detweiler-Short; Keith Stockerl-Goldstein; Asra Ahmed; Terri Jobkar; Diane E Durecki; Kathryn McDonnell; Melissa Mietzel; Daniel Couriel; Mark Kaminski; Ravi Vij
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India.

Authors:  Nithin Sashidharan; Smita Shenoy; Meena Kumari Kamal Kishore; Harish Thanusubramanian
Journal:  J Clin Diagn Res       Date:  2015-05-01

3.  Salvage second hematopoietic cell transplantation in myeloma.

Authors:  Laura C Michaelis; Ayman Saad; Xiaobo Zhong; Jennifer Le-Rademacher; Cesar O Freytes; David I Marks; Hillard M Lazarus; Jennifer M Bird; Leona Holmberg; Rammurti T Kamble; Shaji Kumar; Michael Lill; Kenneth R Meehan; Wael Saber; Jeffrey Schriber; Jason Tay; Dan T Vogl; Baldeep Wirk; Bipin N Savani; Robert P Gale; David H Vesole; Gary J Schiller; Muneer Abidi; Kenneth C Anderson; Taiga Nishihori; Matt E Kalaycio; Julie M Vose; Jan S Moreb; William Drobyski; Reinhold Munker; Vivek Roy; Armin Ghobadi; H Kent Holland; Rajneesh Nath; L Bik To; Angelo Maiolino; Adetola A Kassim; Sergio A Giralt; Heather Landau; Harry C Schouten; Richard T Maziarz; Joseph Mikhael; Tamila Kindwall-Keller; Patrick J Stiff; John Gibson; Sagar Lonial; Amrita Krishnan; Angela Dispenzieri; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-05       Impact factor: 5.742

Review 4.  Does my patient with a serum monoclonal spike have multiple myeloma?

Authors:  Giada Bianchi; Irene M Ghobrial
Journal:  Hematol Oncol Clin North Am       Date:  2012-04       Impact factor: 3.722

5.  Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment.

Authors:  Amy Wu; David Liao; Thea D Tlsty; James C Sturm; Robert H Austin
Journal:  Interface Focus       Date:  2014-08-06       Impact factor: 3.906

6.  AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.

Authors:  Aneel Paulus; Kasyapa Chitta; Sharoon Akhtar; David Personett; Kena C Miller; Kevin J Thompson; Jennifer Carr; Shaji Kumar; Vivek Roy; Stephen M Ansell; Joseph R Mikhael; Angela Dispenzieri; Craig B Reeder; Candido E Rivera; James Foran; Asher Chanan-Khan
Journal:  Br J Haematol       Date:  2013-11-17       Impact factor: 6.998

7.  An Unusual Cause of Altered Mental Status in Multiple Myeloma: An Extraosseous Manifestation.

Authors:  Veeravich Jaruvongvanich; Ittikorn Spanuchart; Pichaya O-Charoen; Christian Kitamura; Lauren Sumida; Marina Roytman
Journal:  Hawaii J Med Public Health       Date:  2016-04

8.  Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.

Authors:  Theresa A Lansdell; Michelle A Hurchla; Jingyu Xiang; Stacy Hovde; Katherine N Weilbaecher; R William Henry; Jetze J Tepe
Journal:  ACS Chem Biol       Date:  2012-12-11       Impact factor: 5.100

9.  Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.

Authors:  Talal Hilal; Mohamad Bassam Sonbol; Vinay Prasad
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

10.  miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.

Authors:  N Amodio; M T Di Martino; U Foresta; E Leone; M Lionetti; M Leotta; A M Gullà; M R Pitari; F Conforti; M Rossi; V Agosti; M Fulciniti; G Misso; F Morabito; M Ferrarini; A Neri; M Caraglia; N C Munshi; K C Anderson; P Tagliaferri; P Tassone
Journal:  Cell Death Dis       Date:  2012-11-29       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.